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Abstract 33 
The nucleic acid guanine-quadruplex structures (G4s) are involved in many aspects of cancer 34 
progression. The DEAH-box polypeptide 36 (DHX36) has been identified as a dominant nucleic 35 
acid helicase which targets and disrupts DNA and RNA G4s in an ATP-dependent manner. 36 
However, the actual role of DHX36 in breast cancer remains unknown. In this study, we observed 37 
that the gene expression of DHX36 was positively associated with patient survival in breast cancer. 38 




By using the xenograft mouse model, we demonstrated that the stable knockdown of DHX36 via 40 
lentivirus in breast cancer cells significantly promoted tumour growth. We also found that, after 41 
the DHX36 knockdown (KD), the invasion of triple-negative breast cancer cells was enhanced. In 42 
addition, we found a significant increase in the number of cells in the S-phase and a reduction of 43 
apoptosis with the response to cisplatin. DHX36 KD also desensitized the cytotoxic cellular 44 
response to paclitaxel and cisplatin. Transcriptomic profiling analysis by RNA sequencing 45 
indicated that DHX36 altered gene expression profile through the upstream activation of TNF, 46 
IFNγ, NFκb and TGFβ1. High throughput signalling analysis showed that one cluster of stress-47 
associated kinase proteins including p53, ROCK1 and JNK were suppressed, while the mitotic 48 
checkpoint protein-serine kinases CDK1 and CDK2 were activated, as a consequence of the 49 
DHX36 knockdown. Our study reveals that DHX36 functions as a tumour suppressor and may be 50 
considered as a potential therapeutic target in breast cancer.   51 
Keywords: DHX36, breast cancer, progression, stress-associated protein, CDK.  52 
 53 
Introduction  54 
Breast carcinoma is one of the most common malignancies in women. Approximately 2.1 million 55 
new cases are diagnosed every year worldwide, which accounts for 25% of all the new female 56 
cancer cases, whereas 0.6 million deaths occur with a 5 year-survival range from 1-37% [1, 2]. 57 
The incidence, mortality rates and survival of breast cancer vary considerably, depending on 58 
complicated risk factors, subtype and stage. For instance, the triple-negative breast cancer (TNBC) 59 
that is characterized by a lack of expression of estrogen receptor (ER), progesterone receptor (PR), 60 
or human epidermal growth factor receptor 2 (HER2), is the most aggressive subtype of the breast 61 
cancer, with the highest rate of relapse and metastasis and the worst overall prognosis than other 62 
breast cancer subtypes. Hormone receptor-positive tumours like luminal A and luminal B can be 63 
treated with endocrine therapy, while a HER2-targeted therapy is usually used when HER2 is 64 
overexpressed. However, there is currently no targeted therapy available for the TNBC, and 65 
chemotherapy is still the main treatment despite high frequencies of resistance. Therefore, novel 66 
biomarkers are needed for a more efficient treatment of some breast cancer subtypes such as TNBC.  67 
DNA and RNA guanine-quadruplex structures (G4s) are often over-represented in gene promoter 68 
regions, regulatory regions of the human genome and untranslated regions of mRNAs.  For 69 
example, G4s have been found in the gene promoters of proto-oncogenes including MYC, KRAS, 70 
BCL-2 and MLL. The G4s are also enriched in the mRNAs of retinoblastoma protein 1 (RB1),  71 
TP53, vascular endothelial growth factor (VEGF), hypoxia-inducible factor 1α (HIF1α), the 72 
transcription factor MYB, platelet-derived growth factor α polypeptide (PDGFA), PDGF receptor 73 
β polypeptide (PDGFRβ), and human telomerase reverse transcriptase (TERT). Therefore altered 74 
G4s have been implicated in cancer development and progression through mediating gene 75 
promotor activity or translation process [3]. 76 
Nucleic acid helicases are a large group of essential enzymes involved in a wide range of major 77 
DNA/RNA processing events, including DNA replication, RNA splicing, mRNA stability, 78 
ribosomal RNA maturation, microRNA processing, ribonucleoprotein (RNP) complex 79 
remodelling and RNA trafficking. The roles of some helicases (e.g. DDX1, DDX3, DDX5, DHX9, 80 
DDX41 and DDX43) in cancer have been well documented. For example, they can regulate 81 




cadherin, and the modulation of some signalling pathways such as Wnt/β-Catenin，L1TD1-RHA-83 
LIN28 and NF-κB signalling pathways [4, 5].  The DEAH-box polypeptide 36 (DHX36) was 84 
originally identified as a dominant ATP-dependent DEAH-box helicase highly specific for DNA 85 
and RNA G4s, and is also termed RNA helicase associated with AU-rich RNA element (RHAU) 86 
or G4 resolvase-1 (G4R1) [6].   87 
DHX36 specifically binds and unwinds the G4-quadruplex motif with its ATPase and resolving 88 
activity. DHX36 has been considered as the major source of RNA G4-resolving activity in HeLa 89 
cell lysate. The depletion of DHX36 protein in HeLa cells causes a dramatic reduction in G4-90 
DNA- and G4-RNA-resolving process. DHX36 contributes to genomic integrity and helps the 91 
transcription and the translation process by unwinding the secondary structures of certain nucleic 92 
acids. DHX36 also modulates some genes containing the G-quadruple forming regions, such as 93 
p53, PITX, YY1, VEGF and ESR1 [7, 8]. For instance, DHX36 regulates p53 pre-mRNA 3'-end 94 
processing following UV-induced DNA Damage. PITX1 protein acts as a tumour suppressor, and 95 
a reduction in its expression is associated with poor overall survival in lung cancer patients [9].  96 
YY1 and VEGF proteins play a multifunctional regulatory role in breast cancer, while ESR1 is a 97 
predictor of clinical response to neoadjuvant hormonal therapy in breast cancer [10-12].  DHX36 98 
can also interact with the pre-miR-134 terminal loop thus reduces the biosynthesis of miR-134 in 99 
neuronal dendrites [13].  Interestingly, miR-134 is implicated as a possible regulator in some 100 
cancer types and this may reinforce the role of DH36 in tumours [14, 15]. It has also been reported 101 
that a long non-coding RNA gene G-Quadruplex Forming Sequence Containing lncRNA (GSEC) 102 
can antagonize DHX36 of its G-quadruplex unwinding activity which subsequently enhances the 103 
migration of colon cancer cells [16]. Despite the scattered findings above, the role of DHX36 in 104 
breast cancer has not been determined. Therefore in this study, we aimed to investigate the 105 
functions of DHX36 in breast cancer cells and its carcinogenesis in vivo.  106 
 107 
Materials and Methods 108 
Cell lines and culture conditions 109 
All the breast cancer cell lines were purchased from the American Type Culture Collection (ATCC) 110 
and maintained at low passage (less than 20). Cells were cultured at 37°C in a humidified incubator 111 
supplied with 5% CO2. The breast cancer cell lines were cultured in Dulbecco’s modified Eagle’s 112 
medium/F12K (Sigma-Aldrich, Dorset, UK) supplemented with 10% foetal calf serum (FCS, PAA 113 
Laboratories Ltd., Somerset, UK), penicillin (100U/ml), and streptomycin (100mg/ml) (Sigma–114 
Aldrich).  115 
Lentiviral infection with DHX36 shRNA 116 
Lentiviral vectors containing short hairpin RNAs (shRNA) specific for DHX36 and the control 117 
shRNA (Scr control) were obtained from VectorBuilder (Santa Clara, CA, USA). The vectors were 118 
assembled with EGFP as a reporter and neomycin resistant gene for selection. HEK293T 119 
packaging cells were transduced with viral packaging (psPAX2), viral envelope (pMD2G) and 120 
lentiviral plasmid vectors using FuGENE 6 transfection reagent (Promega, Southampton, UK) in 121 
serum-free OPTI-MEM (Invitrogen, Carlsbad, CA, USA). Four and five days after transfection, 122 
the supernatant containing the packaged viral particles was collected and filtered through a 0.45um 123 
filter. MDA-MB-231 and BT549 breast cancer cells were then infected using the lentiviral 124 




selected with 1.2 mg/ml G418 for 7 days, and maintained in a growth medium with 300ug/ml 126 
G418. After selection, the stable breast cancer cell lines spontaneously expressed GFP which could 127 
be visualized under a fluorescence microscope. 128 
Drug cytotoxicity assay 129 
Breast cancer cells at a density of 8000 cells/well were seeded into 96-well plates and starved using 130 
a medium containing 2% FCS. Cells were then treated with a serial dilution of cisplatin (Tocris 131 
Cookson Ltd., Bristol, UK), paclitaxel (Tocris) and flavopiridol (Cambridge Bioscience, 132 
Cambridge, UK), respectively. The vehicle control of cisplatin was ddH2O, while the vehicle 133 
control of paclitaxel and flavopiridol was DMSO. After treatment for 24 and 48 hours, the cells 134 
were stained with Alamar Blue (Bio-Rad, Cambridge, MA, USA) following the manufacturer’s 135 
instruction.  The fluorescence was read with an excitation wavelength of 530 nm and the emission 136 
at 590 nm using a Glomax Multi Detection System (Promega). 137 
Cell-matrix adhesion assay 138 
Tissue culture plates (96-well black-well) were pre-coated with 3 mg/ml of Matrigel Matrix in 139 
serum-free medium (BD Biosciences, San Diego, CA, USA) and left overnight at 37℃. Cells at a 140 
density of 10,000 cells/well were seeded onto the pre-coated plates. Following incubation for 1 141 
hour, the non-adherent cells were washed off with PBS. The adherent cells were stained with 1 142 
µM of Calcein AM (eBioscience, Hatfield, UK) for 30 minutes at 37℃.  The fluorescence which 143 
is proportional to the number of the adhesive cells was read with an excitation wavelength of 485 144 
nm and the emission at 520 nm using a Glomax Multi Detection System (Promega Wisconsin 145 
USA). 146 
Electric cell-substrate impedance sensing (ECIS) 147 
The migration ability of breast cancer cell lines was monitored using the ECIS system. Briefly, 148 
MDA-MB-231 and BT549 cells at a density of 2.5x104 cell/well were seeded onto ECIS 96W1E 149 
array plates (Applied Biophysics Inc. NY, USA). And the electrical resistance, due to the 150 
interaction of cells and gold-coated electrodes, was recorded. Once a confluent monolayer was 151 
formed, the cells were subjected to an electric wound at 2800 µA, 60 kHz for 20 seconds and the 152 
rate of change in impedance, as cells migrated onto the electrode sensing area, was subsequently 153 
monitored and analysed. 154 
Transwell invasion assay 155 
The membrane of 24-well inserts with an 8 µm pore size (Greiner Bio-one, Frickenhausen, 156 
Germany) was pre-coated with 300 µg/ml of Matrigel for 2 hours at 37℃. 1x105 cells were then 157 
seeded onto the top chamber in 400 µl of serum-free medium, and 600 µl of the same medium 158 
containing 10% FCS was added to the lower chamber. After incubation for 24 hours, the invaded 159 
cells were detached with 400 µl of HyQtase Dissociation solution (HyClone, Logan, UT, USA) 160 
and stained with 1 µM calcein AM for 1 h. The cell solution was then transferred to a 96-well 161 
black-well plate at a volume of 100 µl/well for 3 wells per group. The fluorescence of invaded 162 
cells was measured using the Glomax Multi Detection System. 163 
Western blotting 164 
Cultured cells were washed twice in PBS and lysed in a RIPA buffer containing 50 mM Tris-HCl, 165 
2% SDS, 5% glycerol, 5 mM EDTA, 1 mM NaF, 10 mM β-glycerophosphate, 1 mM PMSF, 1 166 




concentration was determined by the Pierce BCA protein assay (Thermo Scientific, Colchester, 168 
UK). After normalization, proteins were separated by sodium dodecyl sulphate-polyacrylamide 169 
gel electrophoresis (SDS-PAGE) and transferred with a semi-dry fast transfer apparatus onto a 170 
PVDF membrane (Merck Millipore Inc., Billerica, USA).  The membranes were blocked with 5% 171 
non-fat dried milk (Marvel, Premier Beverages, Stafford, UK) in PBST solution (0.05% Tween-172 
20 in PBS) for 1 h at room temperature. The membranes were then incubated with the primary 173 
antibodies diluted in 5% milk and left overnight at 4˚C. Following wash three times with PBST, 174 
the membranes were incubated with a diluted HRP-conjugated secondary antibody for 1 h at room 175 
temperature. The primary antibodies were anti-JNK (diluted 1:1000. Sc-571,  Santa Cruz 176 
Biotechnology, Santa Cruz, CA, USA), anti-pJNKThr 183/Tyr 185 (diluted 1:1000. sc-6254, Santa 177 
Cruz), DHX36 (diluted 1:1000. GTX131179, GeneTex, San Antonio, TX, USA) and β-actin 178 
(diluted 1:5000. sc-53142, Santa Cruz). The HRP-secondary antibodies (A5278, Anti-Mouse IgG; 179 
A0545, Anti-Rabbit IgG) were diluted at 1:2000 (Sigma-Aldrich, Dorset, UK).  Protein detection 180 
was performed using an EZ-ECL chemiluminescence kit (Biological Industries USA, Inc., 181 
Cromwell, CT, USA). Immunoreactive bands were visualized and quantified by densitometry 182 
using the Syngene G: BOX chemiluminescence imaging system and Gene Tools 4.03 (Syngene 183 
Europe, Cambridge, UK). 184 
Reverse transcription (RT) and real-time PCR analysis 185 
RNA was extracted from the cultured cells at the 60-80% confluency in T25 flasks using TRI 186 
Reagent (Sigma-Aldrich, Dorset, UK). Total RNA (500 ng) was reverse-transcribed to 187 
complementary DNA (cDNA) using Goscript Reverse Transcription mix (Promega). Following 188 
dilution of cDNA at a ratio of 1:8, the quantitative real-time PCR was performed based on an 189 
Amplifluor™ technology, in which a 6-carboxy-fluorescein-tagged Uniprimer™ (Biosearch 190 
Technologies, Inc., Petaluma, CA, USA.) was used as a probe along with a pair of specific primers 191 
with an addition of a Z-sequence (actgaacctgaccgtaca) to the 5'-end of the reverse primer [17]. The 192 
primer sequences for qPCR were: DHX36 forward primer, GTTTAAATCAGTTAACCAGACAC; 193 
DHX36 reverse primer, ACTGAACCTGACCGTACACGCAATGTTGGTAGCAATTA; JNK 194 
forward primer, CTACAAGGAAAACGTTGACA; JNK reverse primer, 195 
ACTGAACCTGACCGTACAGAACAAAACACCACCTTTGA; β-actin forward primer, 196 
CATTAAGGAGAAGCTGTGCT; β-actin reverse primer, ACTGAACCTGACCGTACA 197 
GCTCGTAGCTCTTCTCCAG. The qPCR assays were run in a StepOnePlus system (Thermo 198 
Fisher Scientific, Waltham, MA, USA) and normalized by the corresponding threshold cycle (CT) 199 
values of β-actin mRNA.   200 
Xenograft Tumour Model    201 
BALB/c female nude mice (6–8-week old) were purchased from Beijing Vital River Laboratory 202 
Animal Technology Co., Ltd (Beijing 100107, China) and bred in a specific pathogen-free (SPF) 203 
animal house at approximately 28 °C in an environment with approximately 50% humidity. They 204 
were randomly assigned to two groups with 10 mice/group. 3x106 of stable MDA-MB-231 cell 205 
lines contains either Scr control or DHX36 shRNA were harvested, resuspended in 0.1 mL of PBS, 206 
and subcutaneously transplanted into mammary fat pads of the allocated mice. Each mouse 207 
received one injection. The Tumour size was measured with a calliper every 3-4 days and 208 
calculated in mm3 using the formula for a prolate spheroid (width2 × length × 0.523). When the 209 
tumour mass reached the maximally allowed size (16 mm in diameter), the mice were imaged 210 




instruction. The mice were then sacrificed and the tumours were excised, photographed and 212 
weighted. The freshly dissected tumours were fixed in 10% formalin overnight and embedded in 213 
paraffin. All the animal experiments were approved by the Institutional Animal Care and Use 214 
Committee of Sun Yat-Sen University Cancer Centre. 215 
Immunohistochemistry (IHC) of tissue microarray 216 
The breast cancer tissue microarrays were purchased from US Biomax Inc. (BR1921b, HBre-217 
Duc140Sur-01 and BR1503e. Rockville, MD, USA). The standard indirect biotin-avidin 218 
immunohistochemical analysis was used to evaluate the DHX36 protein expression. Briefly, the 219 
microarray slides were placed in an oven with 50 ˚C for 1 day to facilitate the adhesion of tissue 220 
sections to the slides. The tissue microarrays were then dewaxed and rehydrated by sequential 221 
treatment (5 min per step) with xylene, xylene/ethanol, a serial dilution of ethanol (100%, 90%, 222 
70%, 50%), distilled H2O and Tris-buffered saline (TBS) buffer. Antigen retrieval was performed 223 
by placing the slides in a plastic container, covered with 0.01 M sodium citrate buffer (pH6.0) 224 
antigen retrieval buffer, and heated in a microwave on full power for 20 minutes. Endogenous 225 
peroxide activity was blocked by incubating the sections with 3% hydrogen peroxide for 10 226 
minutes. After 1 hour of pre-incubation in 5% normal goat serum to block nonspecific staining, 227 
the sections were incubated with 7.5 µg/ml of the DHX36 antibody (GTX131179. GeneTex) 228 
overnight at 4˚C. The slides were then washed four times with TBS, and incubated with a universal 229 
biotinylated secondary antibody (ABC Elite Kit, Vectastain Universal, PK-6200, Vector 230 
Laboratories, CA, USA) for 30 minutes. Following washing with TBS, the sections were incubated 231 
with avidin-biotin-peroxidase complex (ABC) for 30 minutes. The 3, 3'-diamino-benzidine (DAB) 232 
substrate (5 mg/ml) was used to develop the final reaction product. The sections were then rinsed 233 
in water, counterstained with Gill's hematoxylin (Vector Laboratories), and dehydrated through a 234 
series of graded alcohols, cleared in xylene and mounted in DPX/Histomount (Merck Millipore, 235 
UK).  Images were captured using an EVOS FL Auto 2 Cell Imaging System (ThermoFisher 236 
Scientific). All IHC images were manually evaluated and scored by two pathologists 237 
independently who were blinded to the clinical information. The immunochemistrical score was 238 
calculated based on intensity plus the percentage of tumour staining. The cut-off value was set as 239 
an upper quarter of the score divided into a high and low expression of DHX36 protein. 240 
Flow cytometry 241 
Cultured cells were detached with trypsin/EDTA and fixed with the IC fixation buffer 242 
(ThermoFisher Scientific) for 1 h at room temperature, then resuspended in ice-cold 100% 243 
methanol, and incubated overnight at -20 ℃. Cells were then washed twice in FACS buffer (2 mM 244 
EDTA in PBS, pH 7.4), blocked with 1% bovine serum albumin (BSA) in PBS with 0.1% Tween 245 
for 1 hour. For the staining with antibodies, cells were incubated with diluted primary antibodies 246 
(1:100) including normal mouse IgG (14-4714-82, ThermoFisher Scientific), cleaved poly (ADP-247 
ribose) polymerase (PARP) (14-6668-82, ThermoFisher Scientific), JNK and p-JNK, respectively, 248 
for 1 hour at room temperature. Cells were then incubated with Alexa Fluor 647-conjugated goat 249 
anti-mouse IgG antibodies (1:1000; A21235, ThermoFisher Scientific) for 30 minutes at room 250 
temperature. For cell cycle analysis, cells were harvested and blocked as described above, and then 251 
directly incubated with Hoechst 33342 (10 µg/ml.  H3570, ThermoFisher Scientific) for 1 hour at 252 
37°C in the dark. Following the final wash with FACS buffer, FACS was performed using BD 253 




Biosciences, San Jose, CA, USA). FACS data were analysed using FCS Express software (version 255 
4. De Novo Software, Los Angeles, CA, USA).  256 
Bioinformatic analysis of gene expression and survival 257 
The association between DHX36 gene expression and the survival of breast cancer patients was 258 
assessed using the pooled gene expression data from www.kmplot.com. The online tool allowed 259 
us to analyse both the OS (overall survival) and RFS (relapse-free survival) from 626 cases of 260 
breast cancer and the RFS from 1764 cases which were subjected to expression profiling with 261 
Affymetrix GeneChip microarray (DHX36 Probeset ID: 223140_s_at). The Auto select best cutoff 262 
was chosen. The differential expression of DHX36 was examined by a pooled analysis of The 263 
Cancer Genome Atlas-Breast invasive carcinoma (TCGA-BRCA) dataset which contains 1097 264 
breast-cancer patients and 114 normal samples.   265 
RNA sequencing (RNA-Seq) 266 
The global transcriptomic profiling was analysed by RNA-Seq on the BGISEQ-500RS sequencer 267 
(BGI, Shenzhen, China) which generated 50-bp paired-end reads. The statistical enrichment and 268 
molecular network of differentially expressed genes (DEGs) were analysed using the Ingenuity 269 
Pathway Analysis (IPA) software (Qiagen, Germany). 270 
Kinexus Kinex antibody microarray 271 
The stable breast cancer cell lines were seeded in T75 flasks and incubated in DMEM 272 
supplemented with 10% FCS at 37℃. When the confluence was approximately 80%, the cells were 273 
then washed twice, and the culture medium was replaced with DMEM with 2% FCS. After 274 
incubation overnight, cells were suspended in lysis buffer, pH 7.4, containing 100mM Tris Buffer, 275 
10% 2-ME, 1% NP-40, protease inhibitor cocktail tablet and 50mM NaF. The lysates were 276 
vortexed and homogenized on a blood wheel for 1 hour at 4 ℃. The supernatant of the lysates was 277 
then collected by centrifugation for 30 minutes at 15,000 rpm at 4 ℃, the protein concentration in 278 
the supernatant was determined by a fluorescamine protein quantification assay (Sigma-Aldrich). 279 
Proteomic analysis of pan-specific and phosphorylated proteins was carried out using a high 280 
throughput Kinex antibody microarrays (900 antibodies, Kinexus Bioinformatics) 281 
(http://www.kinexus.ca/services).   282 
Statistical analysis 283 
For quantitative measurement, including cell-based assays and gene expression profiling, the 284 
Shapiro-Wilk test was used to verify whether the data were normally distributed. For the 285 
comparison of the difference from two subjects, an unpaired t-test was used for data with normal 286 
distribution, whereas, for non-normal distribution, the Mann-Whitney Rank Test was applied. 287 
When more than two sets of data were compared, either One-Way ANOVA or the non-parametric 288 
Kruskal-Wallis test was used. Pearson chi-square test was used to test the association of the 289 
categorized scoring data from tissue microarray IHC staining and clinical features. Graphs and the 290 
statistical analysis were performed using R (version 3.6.1, https://www.r-project.org) or GraphPad 291 
Prism 8 software (GraphPad Software, San Diego, CA, USA). Statistical significance was 292 
indicated with the following nomenclature: *p˂0.05, **p˂0.01, ***p˂0.001unless the p-values 293 






Lower gene expression of DHX36 is associated with poorer survival 297 
We assessed the prognostic value of DHX36 gene expression in breast cancer using the Kaplan–298 
Meier plotter containing 1764 samples from breast cancer patients. As shown in Fig. 1A and 1B, 299 
lower expression of DHX36 mRNA correlated to poorer OS (HR=0.63 (0.45-0.88). p=0.0059) and 300 
RFS (HR=1.32 (1.13-1.54). p<0.001) when all the types of breast cancer were pooled together. 301 
We then analysed the differential expression of the DHX36 gene in the database of the TCGA 302 
invasive breast carcinoma (TCGA-BRCA). It showed that there is a lower level of DHX36 gene 303 
expression in primary tumour compared to normal tissue control (p=0.0092; Fig. 1C). The DHX36 304 
gene expression was downregulated in the later stages (T3+T4) of the breast carcinoma compared 305 
to the earlier stages (T1+T2) (p=0.0096, Fig. 1D). Also, it appeared that the gene expression level 306 
of DHX36 was higher in TNBC (n=123) than in non-TNBC (n=605) (p<0.0001, Fig. 1E)  307 
Low level of the DHX36 protein also predicts poor survival as indicated by tissue microarray 308 
IHC 309 
We then estimated the IHC staining of the DHX36 protein in breast cancer tissue microarrays from 310 
patient specimens. As shown in Table 1 and Figure 1F&G, the samples from patients at a higher 311 
stage (2&3) showed weaker staining of DHX36 (score 0&1) (p=0.034 than lower stage). When 312 
we compared the different pathological types, the frequency of the lower stained DHX36 was 313 
higher in IDC (214/277=77.26%) than in ILC (3/81=3.70%) and in adjacent normal tissue 314 
(9/34=26.47%) (p<0.001).  The expression level of the DHX36 protein also appeared to be 315 
associated with the pathological diagnosis (p<0.001), HER2 intensity (p<0.001), ER intensity 316 
(p<0.001) and PR intensity (p<0.001).  We then performed Kaplan-Meier survival analysis using 317 
a dataset of one array with definite follow-up status (n=140, #HBre-Duc140Sur-01). A higher level 318 
of DHX36 protein expression correlated with favourable survival of breast cancer patients (Figure 319 
1H). The thumbnail IHC images of the three tissue microarrays were shown in Supporting 320 
Information Fig. S1.  321 
Knockdown of DHX36 in TNBC cells increased the invasion ability and suppressed the 322 
migration of the tumour cells in vitro 323 
To understand the role of DHX36 in breast cancer, we selected two TNBC cell lines for a stable 324 
DHX36 knockdown after initial evaluation of the gene and protein expression levels of DHX36 in 325 
a panel of breast cancer cells (Supporting Information Fig. S2). As shown in Figure 2, after the 326 
establishment of the stable knockdown cell lines using BT549, all three shRNAs (1, 2 and 8) 327 
reduced the gene expression of DHX36 when compared with scramble (Scr) shRNA and wild-type 328 
(WT) controls (Figure 2A). Likewise, this was also the case in the stable cell lines developed from 329 
MDA-MB-231 (Figure 2B). The Western blotting images also showed that in BT549, the DHX36 330 
protein level was dramatically reduced in all three cell subsets (shRNA 1, 2 and 8) with the 331 
shRNA2 showing the best efficiency (Figure 2C).  As expected, the WT and Scr controls showed 332 
a higher expression of DHX36 protein. The efficiency of shRNA2 was subsequently demonstrated 333 
in the stable cell lines developed from MDA-MB-231. Therefore in the following experiments, 334 
only the stable cell lines with shRNA2 were utilised (named as shRNA unless otherwise described).   335 
We then evaluated the effect of DHX36 expression on tumour cell invasion using the Matrigel-336 
coated transwell chamber. As shown in Figure 2E, in BT549 cells, DHX36 shRNA increased the 337 
invasion by 6.39% compared to the Scr control (p<0.0001). Similarly, in MDA-MB-231 cells, 338 
DHX36 shRNA increased the invasion by 10.83% compared to the Scr control (p=0.041. Figure 339 




inhibited the migration of the breast cancer cells after the electric wound (p<0.01 vs. Scr control, 341 
respectively. Figure 2G-H).   342 
 343 
Knockdown of DHX36 in TNBC cells increases the S-phase cell population and de-sensitize 344 
the apoptotic response to cisplatin.   345 
We investigated the role of DHX36 in the cell cycle by flow cytometry. As shown in Figure 3, 346 
DHX36 knockdown in the BT549 stable cell lines increased the S-phase population to 36.23% 347 
from 25.91% (Scr). Similarly, in the MDA-MB-231 stable cell line, DHX36 knockdown increased 348 
the S-phase cell population to 43.65% from 33.37% (Scr).  349 
We then evaluated the effect of DHX36 knockdown on apoptosis of the breast cancer cells using 350 
the cleaved PARP as an indicator. In the BT549 stable cell lines, the knockdown of DHX36 351 
decreased the basal apoptotic level by approximately 19.96% compared to its Scr control (Figure 352 
3E&3F); cisplatin (16 µM, 24 hours) increased the apoptosis of the Scr control by approximately 353 
45.14%, but just increased the apoptosis of the DHX36 knockdown group by approximately 18.62% 354 
in comparison to its vehicle (PBS) control (Figure 3G&3H). In the MDA-MB-231 stable cell  lines, 355 
the knockdown of DHX36 decreased the basal apoptotic level by approximately 26.06% compared 356 
to its Scr control (Figure 3I&3J); cisplatin increased the apoptosis of the Scr control by 357 
approximately 69.53%, and increased the apoptosis of the DHX36 knockdown group by 358 
approximately 69.69% in comparison to its vehicle (PBS) control (Figure 3K&3L). The data, 359 
therefore, suggest that DHX36 may modulate the intrinsic apoptosis of breast cancer cells. And it 360 
appeared that cisplatin raised a stronger apoptotic response in MDA-MB-231 cells than BT549 361 
cells.  362 
 363 
Knockdown of DHX36 desensitizes the susceptibility of breast cancer cells to 364 
chemotherapeutic drugs in a cell- and dose-dependent manner.  365 
We then evaluated the cytotoxic response of breast cancer cells to some chemotherapeutic drugs 366 
including paclitaxel and cisplatin, respectively. As shown in Figure 4A, in MDA-MB-231 cells, 367 
following 24-hour treatment, the decrease of cell viability started to be observed from 5nM 368 
paclitaxel in the Scr group, while the DHX36 knockdown group showed the viability decrease 369 
from10 nM.  The suppression of the cellular susceptibility to paclitaxel by DHX36 knockdown 370 
can be seen from 5 nM to 40 nM in comparison to the Scr controls (p<0.01 vs Scr, respectively). 371 
The response difference between the two stable MDA-MB-231 cell lines to paclitaxel began to 372 
disappear following treatment for 48 hours (Figure 4B).  Similarly, the lower level of cytotoxic 373 
response to paclitaxel was observed in the DHX36-knockdown BT549 cell line compared to the 374 
Scr control after treatment for 24 hours (Figure 4C).  Again, the response difference of the two 375 
stable BT549 cell lines to paclitaxel began to disappear following treatment for 48 hours (Figure 376 
4D).  Independent to the effect of DHX36 knockdown, we noticed that the control BT549 cell line 377 
was more sensitive to paclitaxel (starting from 2.5 nM) compared to the control MDA-MB-231 378 
cell line (starting from 5 nM).   Following treatment with multiple doses of cisplatin for 24 hours, 379 
the DHX36-knockdown MDA-MB-231 cell line showed a higher proliferation ratio thus lower 380 
cytotoxicity in response to the doses of 32 µM (p<0.05) and 64 µM (p<0.01) than the Scr control 381 




observed to sustain following treatment for 48 hours (p<0.01 for the two high working doses) 383 
(Figure 4F). Likewise, In BT549 cells, DHX36 knockdown also led to a reduction of the cellular 384 
response to cisplatin following treatment for 24 and 48 hours (Figure 4G&4H). We also confirmed 385 
that the control BT549 cell line was more sensitive to cisplatin (starting from 1 µM) compared to 386 
the control MDA-MB-231 cell line (starting from 4 µM). 387 
Knockdown of DHX36 promotes breast cancer development in a mouse xenograft 388 
To examine whether the DHX36 knockdown promotes breast cancer growth in vivo, we inoculated 389 
the stable MDA-MB-231 cells with and without DHX36 knockdown in nude mice. The in-vivo 390 
fluorescence imaging analysis indicated that all the nude mice showed some tumour growth after 391 
implantation with the stable cell lines containing either the Scr control (Figure 5A) or the DHX36 392 
shRNA(Figure 5B), and tumours with bigger sized could be visualized from the group of the 393 
DHX36 shRNA. The quantification of individual tumour fluorescence images confirmed that the 394 
mice group of the DHX36 shRNA had larger total tumour pixels (proportional to tumour size) 395 
compared to the Scr control (p<0.01. Figure 5C). Likewise, the mice group of the DHX36 shRNA 396 
showed a higher level of integrated density of tumour fluorescence (proportional to tumour mass 397 
density) compared to the Scr control (p<0.05. Figure 5D). The data of the time-lapse physical 398 
measurement of the xenograft mice indicated that the mice with the DHX36 knockdown started to 399 
develop a bigger tumour mass (average tumour volume in mm3) than the Scr control after 2 weeks, 400 
and continued the trend of accelerated tumour growth until the end of examination at Day 46 401 
(p<0.001, Figure 5E). No significant change of body weight was observed between the two mice 402 
groups over the course of measurement (p>0.05, Figure 5F).  The dissected tumours from  the mice 403 
group containing the DHX36 knockdown cells at the endpoint (Day 46) presented larger tumours 404 
(Figure 5G).  The measurement of the tumour weight confirmed that the tumours from the DHX36 405 
shRNA group were dramatically heavier than the Scr control (p<0.001, Figure 5H). This result 406 
therefore indicated that knockdown of DHX36 in MDA-MB-231 cells promoted tumourigenesis, 407 
suggesting that DHX36 expression may be crucial for the suppression of neoplastic growth. 408 
 409 
RNA-Seq transcriptome analysis of stable breast cancer cells indicates that DHX36 is 410 
involved in multiple gene regulation pathways.  411 
We performed an RNA-Seq transcriptome analysis to examine the gene expression profile altered 412 
by DHX36 shRNA. Overall, following DHX36 knockdown, 2.05% of genes were regulated in 413 
BT549 cells, while 1.90 % of genes were regulated in MDA-MB-231 cells (Figure 6A and B). The 414 
top 10 upregulated genes by DHX36 knockdown in both the breast cancer cell lines were CHI3L2, 415 
MAF, SNAI1, BMP2, ADRA2C, HSD17B10, TGM2, DYNLRB1, SNX15 and RAP1GAP2. And 416 
the top 10 downregulated genes were MMP1, MRGPRF, NLRP10, ATP10A, SUSD2, FAM167A, 417 
ITGB2, CYP26B1, UXS1 and PCSK1N (Heatmap showed in Figure 6C).  As indicated by the 418 
gene ontology analysis, DHX36 knockdown altered gene regulation of cell-to-cell signalling and 419 
interaction, cellular growth and proliferation, cell signalling and other cellular function (Figure 420 
6D). The upstream regulator of these genes could be some cytokines or complex such as TNF, 421 
IFNγ and NFκB, as predicted by using the Ingenuity® Pathway Analysis (IPA) (Figure 6E).      422 
DHX36 plays its role in breast cancer cells through stress-associated proteins and mitotic 423 




We used the Kinex antibody array to determine the molecular signalling mechanisms of DHX36 425 
induced invasion and tumourigenesis in breast cancer cells.   As shown in Figure 7, two clusters 426 
of proteins were identified to be differentially expressed following the DHX36 knockdown. In 427 
DHX36 deficient MDA-MB-231 cells, within the cluster of the stress associated kinase proteins, 428 
the pan-specific p53, and the phosphorylated p53 protein isoform of S6 were reduced by 47 % and 429 
30%, respectively. Within the same cluster, the pan-specific and phosphor (Y913) forms of 430 
ROCK1 were also decreased by 34% and 28%, respectively. We also observed the inactivation of 431 
the other phosphorylated stress-associated kinase proteins including MYPT1 (T696), MDM2 432 
(S166) and MLC (S19).  However, following DHX36 knockdown, the cluster of the Mitotic 433 
checkpoint protein-serine kinase proteins was found to be activated. The levels of the 434 
phosphorylated proteins of CDK1/2 (T161), CDK1 (T14), CDK1 (T161), CDK1/2 (T14+Y15), 435 
CDK1 (T14+Y15) were increased by 133%, 109%, 80% and 60%, respectively. The original 436 
images of the Kinex antibody array analysis were shown in Supporting Information Fig. S3.  437 
To instigate whether the increase in the CDK levels in the breast cancer cells has an effect on the 438 
response susceptibility when CDK is inhibited. We performed proliferation after 48h treatment 439 
with to flavopiridol, a CDK inhibitor by ATP competition. The results showed that after DHX36 440 
knockdown, MDA-MB-231 cells were more sensitive to the inhibitory effect of flavopiridol at 441 
different doses including 100 nM (p=0.0087), 200 nM (p=0.0044) and 400 nM (p=0.0022) 442 
(Supporting Information Fig. S4A). BT549 also showed a higher sensitivity following DHX36 443 
knockdown at a dose from 50 nM (p=0.0043) to higher doses including 100 nM (p=0.0022), 200 444 
nM (p=0.0022) and 400 nM (p=0.0022) (Supporting Information Fig. S4B). 445 
By FACS analysis, we also found that, following the knockdown of DHX36 in BT549 cells, the 446 
total and phosphorylated protein levels of JNK were reduced by 36.66 and 35.50%, respectively 447 
(Figure 7C-F). Similarly, in DHX36-deficient MDA-MB-231 cells, the total and phosphorylated 448 
protein levels of JNK was reduced by 20.57 and 16.92%, respectively (Figure 7G-J). The reduction 449 
of JNK and pJNK in both cell lines following the DHX36 knockdown, was confirmed by Western 450 
blotting (Figure 7K). The qPCR data indicated that the JNK gene expression level was 451 
downregulated in cells with the DHX36 shRNA (Figure 7L).   452 
 453 
Discussion 454 
There are enormous challenges to elucidate the molecular mechanisms that lead to breast cancer 455 
progression and identify new biomarkers for the early detection of this disease[18].  RNA helicases 456 
could participate in tumour development and aggression by remodelling complex RNA structures 457 
or altering translation of some pro-oncogenic mRNAs [19, 20]. DHX36 is one of the members of 458 
the DEAH-box helicases, but its role in breast cancer remains unknown.  459 
In this study, we identified that DHX36 acts as a prognostic marker in breast cancer. By using the 460 
Kaplan Meir survival analysis, we showed that a higher gene expression level of DHX36 is 461 
associated with a better OS and RFS in breast cancer patients. Interestingly, the gene expression 462 
level of DHX36 in the TNBC is higher than in non-TNBC subtypes. The IHC data indicate that in 463 
breast cancer tissues, elevated levels of DHX36 correlate with better overall survival. This is 464 
confirmed by the findings in breast cancer tissues, where high levels of DHX36 are associated 465 




In addition, the lower staining of DHX36 was observed more frequently in the invasive ductal 467 
carcinoma (IDC) than in the invasive lobular carcinoma (ILC) tissues. IDC and ILC are different 468 
in multiple clinicopathological features and it is believed that ILC has a favourable response to 469 
systemic therapy compared to IDC [21].  However, the pooled analysis using the KM-Plot online 470 
database indicates that the DHX36 gene expression level may be positively associated with 471 
metastasis and short survival in other solid tumours, such as ovarian and gastric cancer. The 472 
contradictory implication of DHX36 in different cancer types may be linked with its functional 473 
complexity and heterogeneity of the molecular cancer pathways in which it is involved.  474 
Both in vitro and in vivo data indicate that DHX36 may inhibit the malignant properties of breast 475 
cancer cells. The stable knockdown of DHX36 in TNBC cell lines increased the invasion and 476 
decreased the migration properties of the breast cancer cells. The cell cycle analysis suggests that 477 
DHX36 deficiency leads to the accumulation of cells in the S-phase of the cell cycle. And the 478 
downregulation of DHX36 in breast cancer cells attenuates the apoptosis of breast cancer cells 479 
both endogenously and in response to cisplatin. In the presence of DHX36 shRNA, breast cancer 480 
cells tend to be more susceptible to the treatments with some chemotherapeutic drugs including 481 
cisplatin, paclitaxel, and epirubicin in terms of cytotoxicity. Our in-vivo work demonstrates that 482 
the loss of DHX36 function in aggressive MDA-MB-231 cells promotes tumour growth. We, 483 
therefore, speculated that the loss of DHX36 drives the cancer progression in breast cancer. 484 
We investigated the role of DHX36 in breast cancer progression through the RNA sequencing 485 
analysis using the DHX36 knockdown cells. The RNA-Seq data indicate that DHX36 is involved 486 
in many regulatory network routes through mediating TNF, IFN, NFκb and TGFβ1. Also, the 487 
altered gene network altered by DHX36 may influence cancer cell behaviour through different 488 
pathways, such as cell-to-cell interaction, cell growth, cell signalling, molecular transport and 489 
metabolism.  It has been shown that DHX36 is involved in TNFα and NFκB activation in monkey 490 
kidney cells in a virus-induced manner [22]. DHX36 can also activate the production of IFNβ in 491 
mouse embryonic fibroblast (MEF) cells or IFNα in dendritic cells by sensing virus stimulation 492 
[23, 24]. We therefore speculate that the activation of certain cytokines and growth factors by 493 
DHX36 can also occur in breast cancer cells. Besides, the RNA-Seq data suggest that the ITGB2 494 
gene is downregulated, and this may lead to the upregulation of the MMP1 signalling pathway. 495 
MMP1 may then downregulate the BMP2 gene, which exerts diverse functions in cancer 496 
development and progression [25]. The knockdown of DHX36 also upregulates the gene 497 
expression of SNAI1 (SNAIL) gene, which is involved in the induction of the epithelial to the 498 
mesenchymal transition process. 499 
The high throughput proteomic profile data indicate that, following the knockdown of DHX36 in 500 
MDA-MB-231 cells, the level of the death-associated kinase proteins is reduced. In particular, 501 
both pan-specific p53 and most of the phosphor-p53 isoforms are decreased in response to the 502 
DHX36 knockdown. It is known that almost all eukaryotic mRNAs are subjected to a multi-step 503 
pre-mRNA 3’-end processing which is coupled to transcription [26].  DHX36 can particularly bind 504 
the p53 RNA G4-forming sequence and therefore maintain p53 pre-mRNA 3’-end processing 505 
following UV-induced DNA damage in lung cancer cells [27].  Both MDA-MB-231 and BT549 506 
cell lines have two types of intrinsic p53 mutation, named p53280R-K  and p53249R-S, respectively 507 
[28]. However, previous studies also suggest that mutant p53 in cancer cells can be either loss-of-508 
function or gain-of-function, and can be stabilized probably through the loss-of-heterozygosity in 509 
response to cellular stress [29, 30]. The protein levels of pan-specific and phosphor- ROCK1 are 510 




pathway in cancer [31] and it is involved in the actin cytoskeleton destabilisation [32]. As 512 
alterations to the actin cytoskeleton can cause changes in various cancer cell properties such as 513 
adhesion, migration, invasion, and EMT, we therefore suggest that the reduced level of migration 514 
in the breast cancer cells following DHX36 knockdown may be attributed to the decrease of 515 
ROCK1.  516 
The protein array data indicate that there is activation by phosphorylation of the mitotic checkpoint 517 
protein-serine kinase proteins CDK1 and CDK2.  CDK1 is one of the cyclin-dependent kinases 518 
(CDKs) which plays a central regulatory role in mitosis initiation and drives cell cycle transition 519 
from the G1 phase to the S phase when CDK2 is lost [33]. CDK2 is required for the G1 phase 520 
progression and the entry progression into the S phase [34]. In breast cancer, cells with a higher 521 
level of CDK2 respond more sensitively to the treatment of paclitaxel [35].  It is known that p53 522 
is an upstream regulator of CDK1 and CDK2 through various downstream effectors such as 523 
p21WAF1/CIP1), 14-3-3-σ, reprimo, CD25, cyclin B1 and PLK1 [36].   524 
We also demonstrated that JNK transcription and JNK phosphorylation are reduced following the 525 
DHX36 knockdown. The JNK signalling pathway can be activated by some extracellular or 526 
intracellular stress such as reactive oxygen species, nitrogen species, UV, inflammation or 527 
cytokines [37, 38].   In cancer, activated JNKs can indirectly mediate some aspects of cell 528 
behaviour such as growth, transformation and apoptosis by phosphorylating its downstream 529 
substrates such as c-Jun, ATF2, ELK1, and p53 [39]. In another way, JNKs may also directly 530 
modulate the apoptosis by the phosphorylation of the pro- and anti-apoptotic proteins in 531 
mitochondria [40].  532 
Chemotherapy resistance remains a major obstacle for the development of an effective breast 533 
cancer treatment strategy.  It is known that CDK protein kinases may interfere with the DNA repair 534 
activity in cancer cells, therefore increasing their sensitivity to certain DNA damaging drugs [41]. 535 
We showed that the knockdown of DHX36 appears to sensitize the response of breast cancer cells 536 
to some cytotoxic chemotherapeutic drugs such as cisplatin, paclitaxel, epirubicin and flavopiridol, 537 
in a dose-dependent manner.  This may be due to the elevated levels of certain CDK family 538 
members following the DHX36 knockdown as described previously (31). Cisplatin, paclitaxel and 539 
epirubicin are known first-line chemotherapeutic drugs. Flavopiridol is a pan-CDK inhibitor which 540 
inhibits CDKs by blocking their ATP-binding sites directly. As one of the most investigated CDK 541 
inhibitor, flavopiridol has been subjected in considerable clinical trials for its anti-tumour efficacy 542 
[42]. Therefore DHX36 may play a role in modulating the therapeutic response of breast cancer 543 
cells although more evidence would be required by further investigation including clinical studies. 544 
 545 
Conclusion 546 
In conclusion, to our knowledge, this is the first study that identifies the functional role of DHX36 547 
in breast cancer. Our data indicate that DHX36 acts as a tumour suppressor in human breast cancer. 548 
The expression level DHX36 is negatively associated with the survival (OS and RFS) of breast 549 
cancer patients. And we believe that the deficiency of DHX36 enhances the invasion property of 550 
breast cancer cells and promotes tumour growth by modulating the p53, JNK and ROCK signalling 551 
pathways and CDKs (as illustrated in Fig. 8). Our study therefore unveils the new roles of the 552 
DHX RNA helicase proteins in cancer cells thus may open a new avenue for developing anti-553 






G4s, guanine-quadruplex structures; DHX36, DEAH-box polypeptide 36; TNBC, triple-negative 557 
breast cancer; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth 558 
factor receptor 2; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; IHC, 559 
immunohistochemistry; ECIS, electrical cell impedance sensing;  IDC, invasive ductal 560 
carcinoma; ILC, invasive lobular carcinoma; CDK, cyclin-dependent kinase. RB1,  561 
retinoblastoma protein 1; VEGF, vascular endothelial growth factor;  HIF1α, hypoxia-inducible 562 
factor 1α;  PDGFA, platelet-derived growth factor α polypeptide;  PDGFRβ, PDGF receptor β 563 
polypeptide;  TERT, human telomerase reverse transcriptase. 564 
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(Description of the figures and tables) 727 
Table 1. The association of the IHC staining intensity of DHX36 and clinical features of breast 728 
cancer patients.  DCIS: ductal carcinoma in situ. IDC: invasive ductal carcinoma. ILC: invasive lobular 729 
carcinoma. NOS: not otherwise specified.  730 
Figure 1. Expression levels of DHX36 gene and protein are associated with the survival and 731 
clinicopathological features of breast cancer patients. The Kaplan-Meier survival curve was plotted using 732 
the pooled gene expression data from www.kmplot.com (Cut-off value: 1257.33. n=1764). (A) OS. (B) 733 
RFS.  (C) DHX36 gene expression is downregulated in the primary tumour as indicated by the analysis of 734 
The Cancer Genome Atlas-Breast invasive carcinoma (TCGA-BRCA) dataset (n=1218). (D) Expression 735 
level of the DHX36 gene is lower in advanced stages (T3+T4) than in earlier stages (T1+T2) as  indicated 736 
by the TCGA-BRCA data. (E) Expression level of the DHX36 gene is higher in TNBC (n=123) than in 737 
non-TNBC (n=405) as indicated by the TCGA-BRCA data. Equivocal: The ER/PR/HER3 status is partially 738 
determined. NDA: No data available for the ER/PR/HER3 status. (F) Frequency of DHX36 staining scores 739 
in different pathological types in breast cancer tissue arrays. (G) Frequency of DHX36 staining scores in 740 
different stages in breast cancer tissue arrays. (H) Kaplan-Meier survival analysis of the breast cancer tissue 741 
arrays following DHX36 staining by immunohistochemistry. Representative images of the differential 742 
staining intensity of DHX36 in normal breast and breast cancer tissues were shown in Supporting 743 
Information Fig. S1. Clinicopathological status of the three tissue microarray slides was provided in Table 744 
1.  745 
Figure 2. Knockdown of DHX36 enhanced invasion but decreased migration of breast cancer cells. (A) 746 
Relative gene expression of DHX36 in BT549 cells following DHX36 knockdown with shRNA. (B) 747 
Relative gene expression of DHX36 in MDA-MB-231 cells following DHX36 knockdown with shRNA. 748 
(C) The expression level of DHX36 protein after stable shRNA knockdown of DHX36 in BT549 cells, as 749 
estimated by Western blotting. (D) The expression level of DHX36 protein after stable shRNA knockdown 750 
of DHX36 in MDA-MB-231 cells, as estimated by Western blotting. (E, F)  Transwell invasion assay using 751 
the stable cell lines derived from BT549 and MDA-MB-231cells, respectively. Cells invaded through 752 
Matrigel-coated membrane inserts (pore size 8 um) were stained with Calcein AM and detached using Cell 753 
Dissociation Solution, and read using a fluorescence plate reader. The cell group with DHX36 shRNA was 754 
compared with the Scr Control. Although the Invasion of the WT control was showed, because WT cells 755 
were not subjected to lentiviral infection and specific G418 selection, they were not directly comparable to 756 
the shRNA groups. Student T-tests were used to compare the difference between shRNA and Scr. (G, H) 757 
Effect of DHX36 knockdown on the migration of breast cancer cells was accessed using the electric cell-758 
substrate impedance sensing system (ECIS). Normalization was performed by setting up the stating 759 
impedance signal for each group to 1. The repeated-measures ANOVA was used to compare the ECIS data 760 
from different cell groups. **p<0.01.  761 
Figure 3. Effect of DHX36 knockdown on cell cycle progression and apoptosis in response to cisplatin. 762 
Hoechst 33342 was used to stain cellular DNA for cell cycle profiling, while the apoptosis level was 763 
determined using a cleaved-PARP (cPARP) antibody. (A, B) Cell cycle analysis of BT549 cells transduced 764 
with Scr control (left) and DHX36 shRNA (right). (C, D) Cell cycle analysis of MDA-MB-231 cells 765 
transduced with Scr control (left) and DHX36 shRNA (right). (E, F, G and H) Level of cleaved-PARP in 766 
BT549 cells transduced with Scr control and DHX36 shRNA, and treated with PBS and cisplatin, 767 
respectively. (I, J, K and L) Level of cleaved-PARP in MDA-MB-231 cells transduced with Scr control and 768 
DHX36 shRNA, and treated with PBS and cisplatin, respectively. The levels of the cleaved-PARP were 769 
indicated using the Median Fluorescence Intensity (MFI). The percentage change of MFI (PC) was 770 
calculated using the equation: PC = (MFItest-MFIcontrol)/ MFIcontrol*100, where control means the Scr 771 
PBS group.  ISO, isotype control.  772 
Figure 4. The viability of breast cancer cells treated with chemotherapeutic drugs. Cells were seeded onto 773 




hour culture and starvation with serum-free medium for 2 hours, cells were then treated with serially diluted 775 
doses of cisplatin and paclitaxel as specified. The viability/cytotoxicity of cells was examined using the 776 
Alamar Blue assay. (A, B) MDA-MB-231 cell lines treated with paclitaxel for 24 and 48 hours, respectively. 777 
(C, D) BT549 cell lines treated with paclitaxel for 24 and 48 hours, respectively. (A, B) MDA-MB-231 cell 778 
lines treated with cisplatin for 24 and 48 hours, respectively. (C, D) BT549 cell lines treated with cisplatin 779 
for 24 and 48 hours, respectively. The comparison of DHX36 shRNA and Scr control was performed using 780 
repeated-measures ANOVA.  *P<0.05, **P<0.01. 781 
Figure 5. DHX36 knockdown promotes tumor growth in a xenograft mouse model. (A, B)  Representative 782 
in-vivo fluorescence images of the breast tumours developed from the mice injected with MDA-MB-231 783 
with Scr control (left) and DHX36 shRNA (right). (C) Tumour size estimated using the in-vivo images.  (D) 784 
Integrated fluorescence density of the tumours based on the in-vivo images.  (E) Dynamics of the average 785 
tumour volume since the injection of tumor cells. (F) Dynamics of the bodyweight of the mice since 786 
injection. (G) The end-point tumours dissected from individual mice (Scr: n=9; DHX36 shRNA: n=10). H, 787 
The end-point tumour weight.  Quantitative data are presented as mean± SEM. ∗p < 0.05, ∗∗p < 0.01, ∗∗p 788 
< 0.001. 789 
Figure 6. RNA-Seq analysis of the stable breast cancer cells after DHX36 knockdown using shRNA.  (A, 790 
B) MA plot indicating the frequency of the differential gene expression after the stable DHX36 knockdown 791 
in BT549 (left) and MDA-MB-231 (right) cells. (C) Heatmap of the differential gene expression profile in 792 
the two breast cancers with DHX36 shRNA against their Scr control (N=3). (D) Cellular functions which 793 
were identified to be mediated by the genes regulated by DHX36 KD by gene ontology analysis for RNA-794 
seq. The threshold is P<0.05. (E) The predicted upstream regulator of the altered gene profile by the DHX36 795 
knockdown. (F) The gene regulation network of the most significantly altered genes by the DHX36 796 
knockdown.  797 
Figure 7. The effect of DHX36 knockdown on signalling pathways of breast cancer cells. (A) The profile 798 
of stress- associated kinase proteins indicated by the Kinex antibody microarray. (B) The profile of mitotic 799 
checkpoint protein-serine kinases indicated by the Kinex antibody microarray. The change of protein level 800 
in the antibody microarray was calculated as %CFC= (SignalKD-SignalScr)/ SignalScr*100 after global 801 
normalization. FACS analysis was conducted to evaluate the endogenous levels of JNK and phosphor-JNK 802 
(pJNK) proteins. (C, D) Levels of total JNK protein in the stable BT549 cell lines with Scr control (left) 803 
and DHX36 shRNA (right). (E, F) Levels of the phosphorylated JNK protein in the stable BT549 cell lines 804 
with Scr control (left) and DHX36 shRNA (right). (G, H) Levels of total JNK protein in the stable MDA-805 
MB-231 cell lines with Scr control (left) and DHX36 shRNA (right). (I, J) Levels of the phosphorylated 806 
JNK protein in the stable MDA-MB-231 cell lines with Scr control (left) and DHX36 shRNA (right). (K) 807 
Western blotting of the JNK and pJNK proteins in the breast cancer cell lines. (L) Real-time qRT-PCR 808 
showing the gene expression level of JNK in the breast cancer lines.  809 
Figure 8. Schematic illustration of molecular mechanisms underlying the tumor suppression mediated by 810 
DHX36 in breast cancer cells.  811 
Supporting Information Fig. S1. Thumbnail images of the IHC staining of DHX36 in three breast cancer 812 
tissue arrays.  813 
Supporting Information Fig. S2. Comparison of DHX36 gene expression in wild-type breast cancer cell 814 
lines determined by qRT-PCR and normalized by GAPDH gene expression (fold = 1).  815 
Supporting Information Fig. S3. Heatmap images of the Kinex antibody microarray for proteomic 816 
analysis in MDA-MB-231 cells. (A) Scr control. (B) DHX36 shRNA. 817 
Supporting Information Fig. S4. Proliferation of the stable breast cancer cell lines in response to 818 
flavopiridol. Cells were seeded onto 96-well black-well plates with an initial density of 1x104 cells/well 819 
with six tests per group. Following 24-hour culture and starvation with serum-free medium for 2 hours, 820 




examined using the Alamar Blue assay. (A) MDA-MB-231 cells. (B) BT-549 cells. The Student’s t-test 822 
was used compare two cell lines for each dose.  823 
Supporting Information Fig. S5. Effect of DHX36 shRNAs on the invasion capacity of stable cells lines. 824 
Transwell invasion assay was performed using the stable cell lines derived from BT549 and MDA-MB-825 
231cells, respectively. Cells invaded through Matrigel-coated membrane inserts (pore size 8 um) were 826 
stained with Calcein AM and detached using Cell Dissociation Solution, and read using a fluorescence plate 827 
reader. Replication points was shown using jitters.  ** P<0.01; ns, no statistic significance.  The data 828 
indicated that both shRNA1 and sh RNA 2 in the cell lines established from BT549 promoted the tumour 829 
cell invasion significantly (p<0.01). In the cell lines established from MDA-MB-231, the knockdown of 830 
DHX36 by the two shRNAs also promoted the cell invasion (p<0.01), and the effect of shRNA1 appeared 831 
stronger than shRNA 2. This not only suggested that the effect is unlikely the off-target effect of shRNA 2 832 
but also confirmed that our finding of the effect of DHX36 on breast cancer cell invasion was reproducible.   833 
Supporting Information Fig. S6. Basal proliferation of the stable breast cancer cell lines. Cells were 834 
seeded at densities of 2500 cells/well and 5000 cells/well in 96-well tissue-culture plates. Proliferation 835 
measured at the designated time points was normalised with value at Hour 0. The Student’s t-test was used 836 
to compare the two cell lines (Scr vs shRNA 2) at each time point. * p<0.05; ** p<0.01; ns, no statistical 837 


























Table 1. The association of the IHC staining intensity of DHX36 and clinical features of breast 861 
cancer patients.  DCIS: ductal carcinoma in situ. IDC: invasive ductal carcinoma. ILC: invasive lobular 862 
carcinoma. NOS: not otherwise specified.  863 
Clinical feature DHX36 intensity P-value (chi-
square test) 0 1 2 3 
Pathological diagnosis        
Adjacent normal  13 6 5 7  
Cystosarcoma phyllodes   0 2 0 0  
DCIS  0 0 0 1  
Fibroadenoma 0 3 0 0  
Intraductal carcinoma   0 3 1 1  
Intraductal carcinoma (sparse) 0 1 0 0  
Intraductal carcinoma with early infiltrate   0 0 1 0  
IDC   34 82 89 48  
IDC (sparse)   0 0 1 0  
IDC and ILC 0 1 0 0  
IDC with ILC 0 0 3 0  
IDC with micropapillary carcinoma     0 1 6 2  
IDC with mucinous carcinoma           0 0 2 2  
IDC with necrosis   0 0 1 1  
IDC (blank)    0 1 0 0  
IDC (sparse)   1 0 0 0  
ILC      55 21 4 0  
ILC (blank)     2 0 0 0  
Mucinous carcinoma    0 0 2 0  
Normal breast tissue     1 0 0 0  
Normal breast tissue (fibrous tissue)     2 0 0 0 1.582E-15 
Stage      
1 7 7 20 6  
2 66 77 57 37  
3 19 23 29 11 0.03446 
HER2 intensity      
Unknown 9 1 1 5  
0 79 30 15 12  
1 3 52 6 2  
2 3 11 4 0  
3 11 17 3 2 2.016E-15 
ER intensity      
Unknown 9 2 2 5  
0 19 61 16 6  
1 16 11 4 2  
2 17 14 1 2  
3 44 22 6 6 1.544E-06 
PR intensity      
Unknown 8 2 3 4  
0 30 75 15 8  
1 22 10 2 2  
2 17 12 3 1  
3 28 11 6 6 6.486E-06 
Pathology      
DCIS 1 0 4 2  
IDC 104 110 3 60  
ILC 1 2 78 0  
Normal 0 9 25 0  
NOS 2 0 5 0 2.20E-16 
 864 
